NCT03698994 · OUTCOME

Progression Free Survival (PFS) in Pediatric Patients Treated With Ulixertinib

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) · Source last updated 2026-06-17

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From initiation of treatment to disease progression, disease recurrence, or death from any cause assessed up to 2 years

What was measured

PFS along with the confidence intervals will be estimated using the Kaplan-Meier method.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2027-01
denom Units Selected: Participants
description: PFS along with the confidence intervals will be estimated using the Kaplan-Meier method.
reporting Status: NOT_POSTED
time Frame: From initiation of treatment to disease progression, disease recurrence, or death from any cause assessed up to 2 years
title: Progression Free Survival (PFS) in Pediatric Patients Treated With Ulixertinib
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice